

UNITED STATES OF AMERICA
before the
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934
Release No. 86243 / June 28, 2019

Admin. Proc. File No. 3-18141

In the Matter of

CELLCYTE GENETICS CORP. and
CHINA PEDIATRIC PHARMACEUTICALS, INC.

NOTICE THAT INITIAL DECISION HAS BECOME FINAL

The time for filing a petition for review of the initial decision in this proceeding has expired. No such petition has been filed by CellCyte Genetics Corp. or China Pediatric Pharmaceuticals, Inc., and the Commission has not chosen to review the decision on its own initiative.

Accordingly, notice is hereby given, pursuant to Rule 360(d) of the Commission's Rules of Practice,¹ that the initial decision of the administrative law judge has become the final decision of the Commission with respect to CellCyte Genetics Corp. and China Pediatric Pharmaceuticals, Inc.² The order contained in that decision is hereby declared final. The initial decision ordered that, pursuant to Section 12(j) of the Securities Exchange Act of 1934, the registrations of each class of registered securities of CellCyte Genetics Corp. and China Pediatric Pharmaceuticals, Inc., are revoked. The revocation is effective as of July 1, 2019.

For the Commission, by the Office of the General Counsel, pursuant to delegated authority.

Vanessa A. Countryman
Secretary

¹ 17 C.F.R. § 201.360(d).

² *CellCyte Genetics Corp., China Pediatric Pharm., Inc., and Hawker Energy, Inc., Initial Decision* Release No. 1368 (Mar. 18, 2019), 2019 WL 1239734. The Central Index Key numbers are: 1325279 for CellCyte Genetics Corp.; and 1354071 for China Pediatric Pharmaceuticals, Inc.